Iradimed Corporation (NASDAQ:IRMD) Short Interest Update

Iradimed Corporation (NASDAQ:IRMD) was the target of a significant increase in short interest in December. As of December 15th, there was short interest totalling 105,000 shares, an increase of 22.0% from the November 30th total of 86,100 shares. Currently, 1.3% of the shares of the stock are sold short. Based on an average daily trading volume, of 39,100 shares, the days-to-cover ratio is currently 2.7 days.

Iradimed Trading Up 0.4 %

IRMD stock traded up $0.22 during midday trading on Tuesday, hitting $55.31. The company had a trading volume of 14,716 shares, compared to its average volume of 48,239. The stock has a market cap of $700.78 million, a price-to-earnings ratio of 37.88 and a beta of 0.82. Iradimed has a 52 week low of $40.18 and a 52 week high of $57.95. The stock’s 50 day moving average price is $53.38 and its 200 day moving average price is $48.86.

Iradimed Announces Dividend

The company also recently declared a quarterly dividend, which was paid on Monday, November 25th. Investors of record on Friday, November 15th were issued a dividend of $0.15 per share. The ex-dividend date of this dividend was Friday, November 15th. This represents a $0.60 dividend on an annualized basis and a yield of 1.08%. Iradimed’s dividend payout ratio is currently 41.10%.

Insiders Place Their Bets

In other news, CFO John Glenn sold 2,500 shares of Iradimed stock in a transaction dated Monday, December 2nd. The stock was sold at an average price of $54.18, for a total value of $135,450.00. Following the transaction, the chief financial officer now owns 4,383 shares in the company, valued at approximately $237,470.94. The trade was a 36.32 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 37.10% of the stock is owned by insiders.

Hedge Funds Weigh In On Iradimed

Hedge funds and other institutional investors have recently modified their holdings of the company. Charles Schwab Investment Management Inc. lifted its position in shares of Iradimed by 189.7% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 66,632 shares of the medical equipment provider’s stock worth $3,351,000 after purchasing an additional 43,635 shares during the period. Oak Ridge Investments LLC bought a new position in shares of Iradimed in the 3rd quarter worth approximately $2,188,000. Eagle Asset Management Inc. purchased a new position in shares of Iradimed in the 3rd quarter valued at approximately $1,239,000. Albert D Mason Inc. bought a new stake in shares of Iradimed during the third quarter valued at approximately $737,000. Finally, Barclays PLC grew its stake in Iradimed by 113.9% in the third quarter. Barclays PLC now owns 23,774 shares of the medical equipment provider’s stock worth $1,196,000 after purchasing an additional 12,657 shares during the period. 92.34% of the stock is owned by institutional investors.

Iradimed Company Profile

IRADIMED CORPORATION develops, manufactures, markets, and distributes magnetic resonance imaging (MRI) compatible medical devices and related accessories, and disposables and services in the United States and internationally. It offers MRidium MRI compatible intravenous (IV) infusion pump system with associated disposable IV tubing sets; MRI compatible patient vital signs monitoring system; and 3600 FMD1 with RALU ferromagnetic detection device.